Page last updated: 2024-08-24

aromasil and Postpartum Amenorrhea

aromasil has been researched along with Postpartum Amenorrhea in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (33.33)	29.6817
2010's	2 (66.67)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Petit, T	1
Climent, MA; Folkerd, E; García, A; Gavilá, J; Guerrero, A; Guillem, V; Martínez, F; Ortiz, B; Ruíz, A	1
Dowsett, M; Hayes, D; Lønning, PE; Santen, RJ; Smith, IE; Walsh, G; Yap, YS	1

Reviews

1 review(s) available for aromasil and Postpartum Amenorrhea

Article	Year
[Endocrine adjuvant treatment specific features for young breast cancer women]. Bulletin du cancer, 2019, Volume: 106, Issue:12S1 Topics: Adult; Amenorrhea; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Goserelin; Humans; Luteolytic Agents; Neoplasm Recurrence, Local; Randomized Controlled Trials as Topic; Selective Estrogen Receptor Modulators; Tamoxifen; Time Factors; Triptorelin Pamoate	2019

Article

Year

[Endocrine adjuvant treatment specific features for young breast cancer women].

Bulletin du cancer, 2019, Volume: 106, Issue:12S1

Topics: Adult; Amenorrhea; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Goserelin; Humans; Luteolytic Agents; Neoplasm Recurrence, Local; Randomized Controlled Trials as Topic; Selective Estrogen Receptor Modulators; Tamoxifen; Time Factors; Triptorelin Pamoate

2019

Other Studies

2 other study(ies) available for aromasil and Postpartum Amenorrhea

Article	Year
Incidence and predictors of ovarian function recovery (OFR) in breast cancer (BC) patients with chemotherapy-induced amenorrhea (CIA) who switched from tamoxifen to exemestane. Annals of oncology : official journal of the European Society for Medical Oncology, 2013, Volume: 24, Issue:3 Topics: Adult; Amenorrhea; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Disease-Free Survival; Drug Substitution; Estradiol; Female; Humans; Incidence; Kaplan-Meier Estimate; Menstruation; Middle Aged; Ovary; Prospective Studies; Recovery of Function; ROC Curve; Tamoxifen; Treatment Outcome	2013
Adjuvant aromatase inhibitors for early breast cancer after chemotherapy-induced amenorrhoea: caution and suggested guidelines. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Jun-01, Volume: 24, Issue:16 Topics: Adult; Amenorrhea; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Estrogen Receptor Modulators; Female; Follicle Stimulating Hormone; Humans; Letrozole; Luteinizing Hormone; Middle Aged; Neoplasm Staging; Nitriles; Ovariectomy; Practice Guidelines as Topic; Tamoxifen; Triazoles	2006

Article

Year

Incidence and predictors of ovarian function recovery (OFR) in breast cancer (BC) patients with chemotherapy-induced amenorrhea (CIA) who switched from tamoxifen to exemestane.

Annals of oncology : official journal of the European Society for Medical Oncology, 2013, Volume: 24, Issue:3

Topics: Adult; Amenorrhea; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Disease-Free Survival; Drug Substitution; Estradiol; Female; Humans; Incidence; Kaplan-Meier Estimate; Menstruation; Middle Aged; Ovary; Prospective Studies; Recovery of Function; ROC Curve; Tamoxifen; Treatment Outcome

2013

Adjuvant aromatase inhibitors for early breast cancer after chemotherapy-induced amenorrhoea: caution and suggested guidelines.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Jun-01, Volume: 24, Issue:16

Topics: Adult; Amenorrhea; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Estrogen Receptor Modulators; Female; Follicle Stimulating Hormone; Humans; Letrozole; Luteinizing Hormone; Middle Aged; Neoplasm Staging; Nitriles; Ovariectomy; Practice Guidelines as Topic; Tamoxifen; Triazoles

2006